

Archives of Cardiovascular Diseases Supplements



JOURNÉES
EUROPÉENNES de la
SOCIÉTÉ
FRANÇAISE de
CARDIOLOGIE

**14-17
janvier
2015**

Paris
Palais des Congrès
2, place de la Porte-Maillot
75017 Paris



JOURNÉES MIREILLE BROCHIER



Société
Française
de Cardiologie



ELSEVIER
MASSON

85022

Vol. 7 – N° 1 – January 2015

Archives of Cardiovascular Diseases Supplements



Official journal of the French Society of Cardiology

Editor-in-Chief

Ariel A. Cohen

Deputy editors

Yves Cottin, Yves Juillière

Editorial board

Philippe Acar, Hélène Eltchaninoff, Jean Ferrières, Jérôme Garot, Stéphane Hatem, Bernard Jung, Pierre Lantelme, Christophe Leclercq, Philippe Ménasché

Statistical consultant

Emanuele Di Angelantonio

How to contact the journal

Ariel A. Cohen, Service de cardiologie, Hôpital Saint-Antoine (pavillon Lemierre), 184, rue du Faubourg-Saint-Antoine, 75571 Paris cedex 12
Tel.: 33 (0)1 49282886 - Fax.: 33 (0)1 49282884 - E-mail: clarisse.barille@sat.aphp.fr or ariel.cohen@sat.aphp.fr

Scientific committee

E. Aliot (France), P. Amouyel (France), M. Böehm (Germany), P. Bonhoeffer (United Kingdom), D. Bonnet (France), E. Bruckert (France), T. Carrel (Switzerland), M. Cohen (United States), A. Cribier (France), N. Danchin (France), J.-C. Daubert (France), J. Davignon (Canada), G. Derumeaux (France), E. Eeckhout (Switzerland), F. Follath (Switzerland), B. Gerber (Belgium), P. Guéret (France), G. Habib (France), A. Hagege (France), M. Komadja (France), B. Kreitmann (France), R. Lang (United States), S. Laurent (France), H. le Marec (France), J. Lima (United States), N. Ludwig (United Kingdom), Z. Mallat (France), G. Marx (United States), J.-L. Monin (France), E. Mousseaux (France), P. Nataf (France), P. Nihoyannopoulos (United Kingdom), G. Parati (Italy), L. Perrault (Canada), L. Pierard (Belgium), B. Prendergast (United Kingdom), S. Priori (Italy), D. Revel (France), V. Roger (United States), R. Rosenhek (Austria), M. Safar (France), M. Sarano (United States), E.J. Schaefer (United States), M. Scherrer Crosbie (United States), J. Schwiter (Switzerland), P. Serruys (Netherlands), M. Simoons (Netherlands), P.G. Steg (France), G. Tomaselli (United States), P. Tornos (Spain), C. Tribouilloy (France), A. Vahanian

Archives of Cardiovascular Diseases Supplements (ISSN 1878-6480)

Address order and payment to Elsevier Masson SAS, Service Abonnements, 62, rue Camille-Desmoulins, 92442 Issy-les-Moulineaux cedex: payment by check or credit card (CB, EuroCard, MasterCard or Visa: indicate no, and expiration date); CCP Paris no 30041 00001 1904540 H 020/70.

Subscriptions begin 4 weeks after receipt of payment and start with the first issue of the calendar year. Back issues and volumes are available from the publisher. Claims for missing issues should be made within 6 months of publication. Includes air delivery.

Journal manager – Brad Stucky. Tel.: (33) 01 71 16 54 42. Fax: (33) 01 71 16 51 84. E-mail: b.stucky@elsevier.com.

Commercial manager – Advertising – Frédérique Baudoin. Tel.: (33) 01 71 16 51 03. Fax: (33) 01 71 16 51 84. E-mail: f.baudoin@elsevier.com. Website: www.compharma.fr

Subscriptions – Tel.: (33) 01 71 16 55 55. Fax: (33) 01 71 16 55 88. E-mail: infos@elsevier-masson.fr

Publisher – Perle Bodossian. E-mail: p.bodossian@elsevier.com

General manager and publishing director / Directeur de la Publication – Daniel Rodriguez

Author enquiries

The contents of each issue as well as the abstracts of the articles published in *Archives of Cardiovascular Diseases Supplements* are available on the website of Elsevier: em-consulte.com

© 2015 Elsevier Masson SAS. All rights reserved

Édité par Elsevier Masson SAS, Société par actions simplifiée à associé unique, au capital social de 47 275 384 € – RCS Nanterre B 542 037 031

Siège social : 62 rue Camille-Desmoulins, 92130 Issy-les-Moulineaux

Actionnaire : Elsevier Holding France

This journal and the individual contributions contained in it are protected under copyright by Elsevier Masson SAS, and the following terms and conditions apply to their use:

Photocopying

Single photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission of the Publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use. Individuals may obtain the necessary permission and pay the corresponding royalties at the Centre français d'exploitation du droit de la copie (20, rue des Grands-Augustins, 75006 Paris, France).

Derivative works

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution. Permission of the Publisher is required for all other derivative works, including compilations and translations.

Electronic storage or usage

Permission of the Publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the Publisher. Address permissions requests to the publisher.

Notice

No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

Imprimé en France par Imprimerie de Champagne, 52 Langres. CPPAP: en cours

Dépôt légal à parution.

Marie Pierre-Yves	0141, 0300	Savouré Arnaud	0536	Feten Frikha	0270, 0273
Marijon Eloi	0388, 0432	Scridon Alina	0295	Feten Triki	0270, 0273
Marin Francisco	0173	Sebag Frederic	0435	Filonenko Maryna	0151, 0383
Marquie Christelle	0372	Séguero Florent	0017	Foudad Hocine	0146
Martin Alix	0076, 0303, 0374, 0382	Sellal Jean-Marc	0018, 0019, 0029, 0034, 0035, 0037, 0038, 0039, 0141, 0300	Gautier Jean François	0194
Massin François	0406			Grandjean Adrien	0352
Maupain Carole	0555			Gueyffier François	0191
Maury Philippe	0364, 0379, 0392, 0395	Selton Olivier	0039	Habbal Rachida	0074
Merghit Rachid	0415	Solnon Aude	0446	Hajem Said	0405, 0411
Metz Damien	0218	Stamboul Karim	0294, 0457	Hammami Mohamed	0405, 0411
Meurice Jonathan	0372	Steinkamp François	0294	Hammami Sonia	0405, 0411
Mielczarek Marc	0035, 0038	Szurhaj William	0444	Harbaoui Brahim	0352
Miralles Aurelien	0076	Taïeb Jérôme	0107, 0131, 0136	Honchar Oleksii	0299, 0305
Mlotek Marcin	0107	Taraszkiewicz Dorota	0017	Ilcenko Iryna	0151
Mondoly Pierre	0364, 0379, 0395	Tassan-Mangina Sophie	0218	Ilchenko Iryna	0383
Monpeurt Christine	0444	Terrier De La Chaise Arnaud	0039	Jonville-Bera Annie-Pierre	0191
Montagnier Christian	0107	Thien Tri Cung	0406	Khettab Fouad	0352
Morel Elodie	0295	Thomann Sarah	0406	Koubaa Nadia	0405, 0411
Moulin-Zinsch Anne	0018, 0034, 0035	Touzery Claude	0457	Kovalyova Olga	0130, 0305
Nazeyrollas Pierre	0218	Trichine Aziz	0415	Kulikova Mariia	0430
Ndjessan Jean Jacques	0303	Valdes Mariano	0173	Lacroix Philippe	0246
Ngantcha Marcus	0136	Vallet M.	0392	Lantelme Pierre	0352
Nicolle Emmanuelle	0261	Vaugrenard Thibault	0136	Le Lez Marie Laure	0191
Nodar Juan Miguel Ruiz	0173	Vaurs C.	0392	Leila Abid	0270, 0273
Nonin Emilie	0295	Verbrugge Eric	0372	Mekarnia Abdelmoumene	0146
Odille Freddy	0141, 0300	Vermeulin Thomas	0536	Merghit Rachid	0146
Olivier Arnaud	0018, 0019, 0029, 0034, 0035, 0037, 0038, 0039, 0141, 0300	Vidal Jean-Sébastien	0456	Messas Emmanuel	0194, 0195
Ouadah Aicha	0372	Villemin Thibaut	0018, 0019, 0029, 0034, 0035, 0037, 0038, 0039, 0059	Miclea Jean Michel	0195
Ourabah Rissane	0456	Vinault Sandrine	0035, 0038, 0048	Mirault Tristan	0194, 0195
Paleiron Nicolas	0126	Vincent Julie	0035, 0038, 0048	Mourad Hentati	0270, 0273
Pangnarind-Heinz Vanida	0126	Vinsonneau Ulric	0126	Paget Vinciane	0352
Pascale Patrizio	0379	Voilliot Damien	0029, 0034, 0037, 0038, 0039, 0141, 0300	Pisella Pierre-Jean	0191
Pasquié Jean-Luc	0406			Raffoux Emmanuel	0195
Pasquier Florence	0456	Waintraub Xavier	0555	Rea Delphine	0194, 0195
Paule Philippe	0126	Wissocque Ludivine	0372	Rousselot Philippe	0195
Pavon Arnaud	0059	Wright Matthew	0435	Saady Redouane	0473
Pelade Christele	0261	Zeller Marianne	0457	Sahar Elaoud	0270, 0273
Pellet Natacha	0076, 0303			Samir Kammoun	0270, 0273
Pellissier A.	0446			Sauguet Antoine	0473
Perrier Marie Cécile	0432			Thulliez Marie	0191
Philibert Séverine	0294			Trichine Aziz	0146
Pinget Michel	0456			Zhuravlyova Larysa	0151
Piot Olivier	0388, 0432			Zouhir Bahloul	0270, 0273
Piquemal Marie	0126	Abdel Nur Abdel Nur	0130		
Pisica George	0456	Ahmed Tounsi	0270, 0273		
Popescu Irina	0038, 0170	Angoulvant Denis	0191		
Prin Sebastien	0059	Ashcheulova Tatiana	0430		
Probst Vincent	0395	Ashcheulova Tetyana	0130		
Quenot Jean Pierre	0059	Baghdadi Dalila	0074		
Rekik Hager	0076, 0303, 0374, 0382	Bejan-Angoulvant Theodora	0191		
Richard Carole	0294	Ben Hamda Khaldoun	0405		
Rijo Nicolas	0170	Benghazi Samia	0074		
Rinaldi Aldo	0435	Benhamda Kaldoun	0411		
Rinaldi Jean Paul	0166	Berriche Olfa	0405, 0411		
Ritz Patrick	0392	Bobronnikova Lesya	0383		
Rizk Joseph	0018, 0019	Bouaguel Ilyas	0146		
Rohel Gwenole	0126	Boussel Loic	0352		
Rollin Anne	0364, 0379, 0392, 0395	Bricca Giampiero	0352		
Ruidavet Jean Bernard	0364	Cautres Thomas	0246		
Ruidavets Jean-Bernard	0017	Charles Paul	0352		
Sacher Frederic	0379, 0395	Courand Pierre-Yves	0352		
Sadoul Nicholas	0432	Dary Patrick	0032		
Sadoul Nicolas	0141, 0300, 0388	Dombret Herve	0194, 0195		
Sadron Marie	0364, 0379, 0395	Dorra Abid	0273		
Saint Etienne Christophe	0173	Doyen Denis	0473		
Salleron Julia	0372	Etukudo Ime Ime	0130		
Saoudi Nadir	0086, 0166, 0170	Fajadet Jean	0473		
Saulnier A.	0392	Ferrari Emile	0473		

Topic 06 - Hypertension / Vascular disease

Topic 07 - Basic science



Methods and Results: From 1998 to 2013, 10 cases of pulmonary embolism were found amongst BD patients in the department of internal medicine of Hedi Chaker Hospital. All these patients fulfilled International Study Group criteria for BD.

10 patients (all men, mean aged at 29.9 ± 9.08 years) were diagnosed as having pulmonary embolism. This was inaugural in 7 cases. Peripheral venous thrombosis was present in 50% of patients; cardiac thrombosis was presented in 2 cases and pulmonary aneurysm in 2 patients. Pulmonary infarction has been noted in 3 cases. Pulmonary artery pressure may be elevated, and may indicate a poor prognosis. Mediastinal lymphadenopathy and mild pleural and pericardial effusions was also observed in 1 case. Protein C, protein S, antithrombin III and homocysteinemia levels were normal in all cases. One patient was positive for IgG anticardiolipin antibody. All our patients were treated successfully by anticoagulation therapy combined with high dose prednisone, colchicine and intravenous cyclophosphamide in 2 patients. After a mean follow-up of 106 ± 49 months, 4 patients had a recurrence of pulmonary embolism and only 1 patient was dead.

Conclusion: Pulmonary embolism is one of the severe and worst prognostic manifestations of the BD. Our knowledge about pulmonary complications of Behçet's disease continues to evolve, but we need controlled trials for the management of the disease. The main goal should be to elucidate the pathogenesis and standardize the management according to the underlying pathologic process.

0299

Interleukins 33 and 1 β , left ventricular geometry and diastolic dysfunction in hypertensive patients with obesity

Oleksii Honchar


Kharkiv National Medical University, Propedeutics To Internal Medicine No.1, Kharkiv, Ukraine

Purpose: To investigate interrelations between interleukin 33 (IL-33) and 1 β (IL-1 β) serum levels, left ventricular (LV) remodeling and diastolic dysfunction (DD) in hypertensive patients with obesity.

Materials and methods: 80 hypertensive patients (51 obese) underwent transthoracic echocardiography. LV geometric pattern by A.Ganau, E/A and E/E' ratios, pulmonary wedge pressure (PWP) by S.Nagueh were calculated. IL-33 and IL-1 β serum levels were estimated using ELISA.

Results: IL-33 and IL-1 β were higher in hypertensive patients ($p < 0.001$), independently of BMI, and formed 4 clusters (see pic.) Cluster 1 was associated with the highest LV myocardial mass index (MMI) ($160.5 (142.8; 185.8)$ g/m², $p < 0.05$), highest prevalence of LV hypertrophy (LVH) (100.0%, 90.0% of concentric LVH), moderate decrease in E' velocity ($9.95 (8.32; 10.60)$ cm/sec), relatively low PWP ($9.23 (8.83; 13.03)$ mmHg) and 70.0% prevalence of LVDD (60.0% of type I). Cluster 2 had LVMMI of ($116.9 (104.4; 163.1)$ g/m²), 55.0% prevalence of LVH plus 30.0% of concentric remodeling, lowest E' ($7.68 (6.50; 9.67)$ cm/sec, $p < 0.01$), highest PWP ($12.26 (10.72; 13.12)$ mmHg, $p < 0.05$) and highest rate of DD (85.0%, 70.0% of type I). Cluster 4 was associated with MMI of $121.4 (111.7; 140.5)$ g/m², 66.7% rate of LVH (equal for concentric and eccentric variants), highest values of E' ($11.04 (9.49; 12.00)$ cm/sec), lowest PWP ($9.07 (7.04; 11.51)$ mmHg) and lowest prevalence of LVDD (66.7%, 50.0% of type I). Cluster 3 ($p > 0.05$ vs control group) had intermediate characteristics of mentioned parameters.

Conclusion: Significant increase in IL-33 and IL-1 β levels in hypertensive patients independently of BMI was revealed. Increase in both cytokines' levels was associated with highest rates of LVH and DD. Prevalent increase in IL-1 β was connected to the worst state of diastolic function despite low rates of hypertrophy. Prevalent increase in IL-33 had the most favorable influence on the severity of LVH as well as diastolic filling (figure above).



Abstract 0299 – Figure

0383

The peculiarities of structural and functional state of myocardium and daily blood pressure profile in hypertensive patients with diabetes mellitus

Lesya Bobronnikova, Iryna Ilchenko, Maryna Filonenko

Kharkiv National Medical University, Kharkiv, Ukraine

Purpose: To establish the relationship between structural and functional parameters of the left ventricle (LV) and daily blood pressure (BP) profile in patients with arterial hypertension (AH) of II stage comorbid with type 2 diabetes mellitus (DM2).

Methods: 68 patients (32 men and 36 women, mean age 49.6 ± 5.2 years); 32 – with isolated hypertension (group 1), 36 – with hypertension and DM2 (group 2) were examined. We evaluated the data of transthoracic echocardiography and parameters of ambulatory blood pressure monitoring.

Results: Patients of the 1st group had a significant increase of the LV posterior wall dimension (LVPWd) – 14% ($p < 0.05$) and left atrial size – 17% ($p < 0.05$). In patients of the 2nd group a direct correlation between BP variability and LVPWd ($r = 0.67$; $p < 0.05$) was revealed; as well as inverse correlation between daily average BP variability and a maximum velocity of early wave of mitral inflow ($r = -0.51$; $p < 0.05$).

Conclusions: In patients with hypertension comorbid with type 2 diabetes mellitus the following changes can be observed: the increase of BP variability, predominance of concentric left ventricular hypertrophy (65% of patients) over the eccentric one (29% patients) with the formation of diastolic dysfunction and impaired LV relaxation (51% of patients).

0430

Features of carbohydrate metabolism, cytokines activity and I/D gene ACE polymorphism at patients with arterial hypertension and overweight

Mariia Kulikova, Tatiana Ashcheulova

Kharkiv National Medical University, Propedeutics To Internal Medicine, Kharkiv, Ukraine

The purpose of our research was to study features of carbohydrate metabolism, activation of the pro-inflammatory cytokine-interleukin-18 (IL-18) and anti-inflammatory cytokine-interleukin-10 (IL-10), I/D gene ACE polymorphism at patients with arterial hypertension and overweight. Design and Methods: 103 hypertensive patients were examined, which have been divided